CL2016002008A1 - Proceso para la elaboración de derivados de pirimidin sulfamida. - Google Patents

Proceso para la elaboración de derivados de pirimidin sulfamida.

Info

Publication number
CL2016002008A1
CL2016002008A1 CL2016002008A CL2016002008A CL2016002008A1 CL 2016002008 A1 CL2016002008 A1 CL 2016002008A1 CL 2016002008 A CL2016002008 A CL 2016002008A CL 2016002008 A CL2016002008 A CL 2016002008A CL 2016002008 A1 CL2016002008 A1 CL 2016002008A1
Authority
CL
Chile
Prior art keywords
sulfamide
elaboration
pyrimidin
derivatives
compounds derived
Prior art date
Application number
CL2016002008A
Other languages
English (en)
Inventor
Stefan Abele
Jacques-Alexis Funel
Ivan Schindelholz
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002008(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2016002008A1 publication Critical patent/CL2016002008A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

PROCESO PARA LA ELABORACION DE COMPUESTOS DERIVADOS DE PIRIMIDIN SULFAMIDA, ANTAGOMISTAS DEL RECEPTOR DE ENDOTELINA; COMPUESTOS INTERMEDIARIOS DERIVADOS DE HALO PIRIDINAS; Y USO DE LOS COMPUESTOS INTERMEDIARIOS PARA ELABORAR COMPUESTOS DERIVADOS DE PIRIDIN SUFAMIDA.
CL2016002008A 2014-02-14 2016-08-10 Proceso para la elaboración de derivados de pirimidin sulfamida. CL2016002008A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14155137.4A EP2907811A1 (en) 2014-02-14 2014-02-14 Process for manufacturing pyrimidine sulfamide derivatives

Publications (1)

Publication Number Publication Date
CL2016002008A1 true CL2016002008A1 (es) 2017-02-03

Family

ID=50073084

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016002008A CL2016002008A1 (es) 2014-02-14 2016-08-10 Proceso para la elaboración de derivados de pirimidin sulfamida.
CL2017000505A CL2017000505A1 (es) 2014-02-14 2017-03-03 Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017000505A CL2017000505A1 (es) 2014-02-14 2017-03-03 Proceso para la elaboración de derivados de pirimidin sulfamida.(div. sol. 2008-2016).

Country Status (28)

Country Link
US (1) US9938244B2 (es)
EP (3) EP2907811A1 (es)
JP (2) JP6431922B2 (es)
KR (2) KR102261695B1 (es)
CN (2) CN105992762B (es)
AR (2) AR099434A1 (es)
AU (2) AU2015217000B2 (es)
BR (2) BR122017005939B1 (es)
CA (1) CA2937277C (es)
CL (2) CL2016002008A1 (es)
CY (1) CY1123319T1 (es)
DK (1) DK3105220T3 (es)
EA (2) EA032460B1 (es)
ES (2) ES2906458T3 (es)
HK (1) HK1243405A1 (es)
HR (1) HRP20201450T1 (es)
HU (1) HUE050974T2 (es)
IL (1) IL251126A0 (es)
LT (1) LT3105220T (es)
MX (1) MX368014B (es)
NZ (1) NZ724273A (es)
PL (1) PL3105220T3 (es)
PT (1) PT3105220T (es)
SA (1) SA516371640B1 (es)
SG (2) SG10201701994RA (es)
SI (1) SI3105220T1 (es)
TW (2) TWI666203B (es)
WO (1) WO2015121397A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095727A1 (es) 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd Preparación de intermediarios de pirimidina
EP2907811A1 (en) * 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives
CN105461638A (zh) * 2015-12-10 2016-04-06 合肥久诺医药科技有限公司 一种马西替坦晶型及其制备方法
CN105461639B (zh) * 2015-12-10 2018-03-09 合肥久诺医药科技有限公司 一种高纯度马西替坦的精制方法
MA49664A (fr) 2017-02-27 2020-06-03 Idorsia Pharmaceuticals Ltd Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
CN109232546B (zh) * 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
EP4056182A1 (en) * 2019-11-07 2022-09-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of aprocitentan, preparation method therefor and use thereof
EP4153574A1 (en) * 2020-05-21 2023-03-29 Teva Pharmaceuticals International GmbH Solid state forms of aprocitentan and process for preparation thereof
WO2023111797A1 (en) * 2021-12-17 2023-06-22 Janssen Biotech, Inc. Pyrimidine sulfamide derivatives and process for manufacturing them
WO2023227721A1 (en) 2022-05-25 2023-11-30 Idorsia Pharmaceuticals Ltd Crystalline forms of sodium (5-(4-bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)(sulfamoyl)amide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3921918A1 (de) * 1989-07-04 1991-01-17 Hoechst Ag Verfahren zur herstellung von 2,4,6-trifluor-1,3,5-triazin
DE60118782T2 (de) 2000-12-18 2007-01-25 Actelion Pharmaceuticals Ltd. Neue sulfamiden und deren verwendung als endothelin-antagonisten
TR200103716A2 (tr) * 2001-12-25 2003-07-21 Ba�Lama Al� Zenginleştirilmiş dizel yakıt kompozisyonu
CN100537546C (zh) * 2002-01-02 2009-09-09 埃科特莱茵药品有限公司 作为内皮素拮抗剂的新型烷基磺酰胺
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
EP2396331B1 (en) 2009-02-13 2013-10-16 Bayer Intellectual Property GmbH Fused pyrimidines as akt inhibitors
US20110082151A1 (en) * 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
KR101471047B1 (ko) * 2012-11-21 2014-12-08 주식회사 메디켐코리아 고순도 보센탄의 개선된 제조방법
CN103012279B (zh) * 2012-11-27 2015-01-28 浙江工业大学 一种4,5,6-三氟嘧啶化合物的制备方法
AR095727A1 (es) 2013-03-27 2015-11-04 Actelion Pharmaceuticals Ltd Preparación de intermediarios de pirimidina
CN103724281A (zh) * 2013-12-03 2014-04-16 镇江圣安医药有限公司 N-[5-（4-溴苯基）-6-[2-[（5-溴-2-嘧啶基）氧基]乙氧基]-4-嘧啶基]-n′-丙基磺酰胺的新型衍生物及其应用
EP2907811A1 (en) 2014-02-14 2015-08-19 Actelion Pharmaceuticals Ltd. Process for manufacturing pyrimidine sulfamide derivatives

Also Published As

Publication number Publication date
TW201613877A (en) 2016-04-16
AR099434A1 (es) 2016-07-20
AU2015217000A1 (en) 2016-09-29
AR107801A2 (es) 2018-06-06
PT3105220T (pt) 2020-09-23
US20160368882A1 (en) 2016-12-22
WO2015121397A1 (en) 2015-08-20
CL2017000505A1 (es) 2017-11-24
BR112016018581A2 (pt) 2017-08-08
JP6421209B2 (ja) 2018-11-07
IL251126A0 (en) 2017-04-30
KR102261695B1 (ko) 2021-06-07
PL3105220T3 (pl) 2020-12-28
AU2015217000B2 (en) 2019-02-14
SI3105220T1 (sl) 2020-10-30
TWI666203B (zh) 2019-07-21
LT3105220T (lt) 2020-10-12
SG10201701994RA (en) 2017-05-30
CA2937277C (en) 2021-07-06
BR112016018581A8 (pt) 2021-06-22
CN107162988B (zh) 2020-08-21
NZ724273A (en) 2020-06-26
CN105992762B (zh) 2019-04-16
ES2819504T3 (es) 2021-04-16
EA201691618A1 (ru) 2017-01-30
HRP20201450T1 (hr) 2020-12-25
CN107162988A (zh) 2017-09-15
BR112016018581B1 (pt) 2022-11-16
EP3105220A1 (en) 2016-12-21
JP2017505801A (ja) 2017-02-23
MX2016010486A (es) 2016-10-31
MX368014B (es) 2019-09-13
HK1243405A1 (zh) 2018-07-13
KR20160122213A (ko) 2016-10-21
EA032933B1 (ru) 2019-08-30
HUE050974T2 (hu) 2021-01-28
EP3214082B1 (en) 2021-11-10
EP2907811A1 (en) 2015-08-19
AU2017202446B2 (en) 2019-03-28
KR20170029656A (ko) 2017-03-15
SG11201606667VA (en) 2016-09-29
JP2017125055A (ja) 2017-07-20
TW201730157A (zh) 2017-09-01
CA2937277A1 (en) 2015-08-20
BR122017005939B1 (pt) 2022-12-20
TWI663155B (zh) 2019-06-21
EP3214082A1 (en) 2017-09-06
BR122017005939A2 (pt) 2019-09-10
US9938244B2 (en) 2018-04-10
EP3105220B1 (en) 2020-07-01
AU2017202446A1 (en) 2017-05-04
EA032460B1 (ru) 2019-05-31
JP6431922B2 (ja) 2018-11-28
EA201790343A1 (ru) 2017-06-30
CY1123319T1 (el) 2021-12-31
KR102406358B1 (ko) 2022-06-07
SA516371640B1 (ar) 2019-09-08
ES2906458T3 (es) 2022-04-18
CN105992762A (zh) 2016-10-05
DK3105220T3 (da) 2020-09-07
NZ729685A (en) 2020-11-27

Similar Documents

Publication Publication Date Title
CL2016002008A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2018000883A1 (es) Moduladores del receptor x farnesoide
CL2016001871A1 (es) Anticuerpos humanos para pd-1
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
EA201691991A1 (ru) Мультиспецифические антитела
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
ES2796903T8 (es) Procedimiento de uso de inmunoconjugados anti-CD79b
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CL2018001481A1 (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
EA201692219A1 (ru) Способы получения противовирусных соединений
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CL2017003147A1 (es) Moduladores de receptor nuclear
DOP2017000110A (es) Receptores quimericos de antígeno anti–cldn y métodos de uso
CL2019001381A1 (es) Método para el tratamiento de glomeruloesclerosis segmentaria focal.
NI201700129A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
CL2017000151A1 (es) Derivados de piridona
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades